Liou Kenny, Thomopoulos Sophia I, Yoo Hannah, Shuai Yuhan, Chehrzadeh Sasha, Arani Arvin, Borowski Bret, Reid Robert I, Jack Clifford R, Weiner Michael W, Jahanshad Neda, Thompson Paul M, Nir Talia M
Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Marina del Rey, CA, USA.
Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
bioRxiv. 2025 Aug 28:2025.08.22.671829. doi: 10.1101/2025.08.22.671829.
Diffusion MRI (dMRI) is a powerful tool to assess white matter (WM) microstructural abnormalities in Alzheimer's disease (AD). The fourth phase of the Alzheimer's Disease Neuroimaging Initiative (ADNI) now includes multiple multishell dMRI protocols, enabling both traditional and advanced dMRI model analyses. There is a need to evaluate whether multishell data offer deeper insights into WM pathology in AD than more widely available single-shell data by overcoming single-shell model limitations. Here, we fit single-shell DTI and multishell NODDI to dMRI data from 533 ADNI3/4 participants to assess their sensitivity to key clinical indicators of AD such as cognitive impairment, amyloid-beta and tau PET burden. Overall, we found that NODDI offered no major advantages in detecting cognitive impairment and tau pathology, but NODDI was marginally more sensitive to amyloid pathology.
扩散磁共振成像（dMRI）是评估阿尔茨海默病（AD）中白质（WM）微观结构异常的有力工具。阿尔茨海默病神经成像计划（ADNI）的第四阶段现在包括多个多壳层dMRI协议，支持传统和先进的dMRI模型分析。有必要评估多壳层数据是否通过克服单壳层模型的局限性，比更广泛可用的单壳层数据能更深入地洞察AD中的WM病理学。在这里，我们将单壳层扩散张量成像（DTI）和多壳层神经突方向离散与密度成像（NODDI）应用于533名ADNI3/4参与者的dMRI数据，以评估它们对AD关键临床指标（如认知障碍、淀粉样β蛋白和tau蛋白PET负荷）的敏感性。总体而言，我们发现NODDI在检测认知障碍和tau蛋白病理学方面没有明显优势，但NODDI对淀粉样蛋白病理学的敏感性略高。
